Use of a WHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study

Lancet Infect Dis. 2011 Jul;11(7):533-40. doi: 10.1016/S1473-3099(11)70057-3. Epub 2011 Apr 20.

Abstract

Background: In 2007, WHO released revised recommendations and an algorithm for the diagnosis and treatment of smear-negative pulmonary tuberculosis in seriously ill people living with HIV/AIDS. We aimed to assess the effect of the recommendations on clinical outcome in patients in South Africa.

Methods: We enrolled seriously ill patients (aged ≥15 years) with HIV infection and suspected smear-negative pulmonary tuberculosis from three hospitals in KwaZulu-Natal, South Africa. Patients were consecutively enrolled into two cohorts: the first cohort was managed according to standard practice, and the second according to the WHO-recommended algorithm. The primary endpoints were rates of continued stay in hospital at 7 days after admission and survival at 8 weeks after admission.

Findings: 338 patients were enrolled in the standard practice cohort between August, 2008, and February, 2009, and 187 were enrolled in the algorithm cohort between March, 2009, and December, 2009. 7 days after hospital admission, 27% (n=50) of patients in the algorithm cohort were still in hospital, compared with 38% (n=130) in the standard practice cohort (rate ratio 0·70, 95% CI 0·53-0·91; p=0·009). 8 weeks after admission, 83% (n=156) of patients in the algorithm cohort were alive, compared with 68% (n=230) in the standard practice cohort (1·23, 1·11-1·35; p=0·0001), with effect modified by hospital location.

Interpretation: In seriously ill patients with HIV infection and suspected smear-negative pulmonary tuberculosis, early antituberculosis treatment according to the WHO algorithm could significantly reduce mortality in South Africa.

Funding: US President's Emergency Plan for AIDS Relief.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Algorithms
  • Anti-HIV Agents / administration & dosage*
  • Antitubercular Agents / administration & dosage*
  • Cohort Studies
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • HIV Infections / microbiology*
  • HIV Infections / mortality
  • HIV*
  • Humans
  • Mycobacterium tuberculosis*
  • Proportional Hazards Models
  • South Africa
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / immunology
  • Tuberculosis, Pulmonary / mortality
  • Tuberculosis, Pulmonary / virology*
  • World Health Organization
  • Young Adult

Substances

  • Anti-HIV Agents
  • Antitubercular Agents